The Epidemiology of the Weiss Cohort Project

Weiss 队列项目的流行病学

• 批准号: 10227898
• 负责人: Stanley H Weiss
• 金额: $ 77.25万
• 依托单位: RBHS-NEW JERSEY MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-15 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10227898
• 关键词: AIDS/HIV problem; ATOD; Accounting; African American; Age; Aging; Agreement; Applications Grants; Authorization documentation; Back; Behavioral; Biological Specimen Banks; Biotechnology; Blood; Caring; Cause of Death; Cessation of life; Cholangiocarcinoma; Chronic; Cohort Studies; Data; Data Set; Death Certificates; Disease; Disease Outcome; Drug Interactions; Drug abuse; Drug usage; Drug user; Enrollment; Epidemic; Epidemiology; Ethnic Origin; European; Evolution; Exposure to; Female; Future; Gender; Genetic; Geography; Goals; Grant; HIV; HIV Seronegativity; HIV risk; Health; Health system plans; Hepatitis C; Hepatitis C virus; Highly Active Antiretroviral Therapy; Hispanics; Human immunodeficiency virus test; Incidence; Individual; Infection; Infectious Agent; Institutes; Intervention; Laboratories; Link; Liver Failure; Liver diseases; Longitudinal Studies; Longitudinal cohort; Longterm Follow-up; Malignant Neoplasms; Malignant neoplasm of liver; Malignant neoplasm of lung; Medical; Minority Groups; National Cancer Institute; National Institute of Drug Abuse; Opioid; Outcome; Outcome Assessment; Participant; Pattern; Persons; Pharmaceutical Preparations; Policies; Population; Prevention; Prospective cohort; Race; Recording of previous events; Registries; Relative Risks; Resources; Risk; Risk Factors; Series; Smoking; Source; Stage at Diagnosis; Survival Analysis; Survivors; Time; Treatment Protocols; Underrepresented Minority; Vital Statistics; Woman; Work; adjudicate; burden of illness; cancer epidemiology; cancer risk; cancer site; clinical epidemiology; clinical practice; cohort; data registry; disorder risk; follow-up; high risk; indexing; male; mortality; neoplasm registry; public health intervention; recruit; sex; tool; treatment program

PROJECT SUMMARY/ABSTRACT The goals of this project are to further our understanding of the long-term clinical epidemiology of health outcomes among drug users who are at high risk for HIV. This is important because it will guide clinical practice and health systems planning in the face of the continuing HIV/AIDS epidemic and the evolving epidemic of drug abuse, including opioids. Many HIV-infected persons are living longer than they had in the past, due to the advent and availability of highly active antiretroviral therapy. We have a unique prospective cohort of drug users established in the 1980s, backed by a linked biospecimen repository and permission for indefinite continuing follow-up, established by the NCI and NIDA for the long- term study of drug users. The cohort numbers nearly 11,000 drug users, who are diverse in gender, race, ethnicity and geography, and include large numbers of both HIV-positive and HIV-negative persons. Hepatitis C virus infection is extremely common in these persons. WE SEEK TO UNDERSTAND THE HEALTH OUTCOMES IN THIS COHORT THROUGH TWO AIMS. AIM 1. To determine the epidemiologic features of mortality outcomes associated with HIV among drug users over a 35-year period. This will be accomplished by matching our cohort to vital statistics registry data. AIM 2. To determine the cancer epidemiology, by cancer site, among drug users over a 35-year period, including incidence, stage at diagnosis, treatment regimens, mortality, and HIV-associated risk. This will be accomplished by matching our cohort to cancer registry data. Our project analyses will integrate these two types of data, with stepwise repetition of matching over several years. Mortality data will enable us to more accurately conduct survival analyses on an array of disease outcomes, with a special focus on cancer to identify putative risk factors. This has the potential to assist with the identification of interventions that would reduce disease burden and prolong survival. We will characterize disease outcomes in HIV-positive compared to HIV-negative drug users, accounting for baseline demographic, behavioral, and medical factors. Our cohort uniquely affords the opportunity to study health outcomes over a prolonged time period spanning several decades in both sexes and in underrepresented minority populations. The size of our study and the extent and richness of baseline data will make it a powerful tool in understanding a wide array of disease outcomes. Given the continuing rapid evolution of biotechnology, future research might employ evolving biotechnology to use our biospecimen repository to explore specific disease outcomes we will be identifying. Our cohort has joined the NIDA Genetics Consortium. We will explore joining other consortia which focus on other outcomes, which could amplify the power of those consortia.

项目总结/摘要 这个项目的目标是进一步了解健康的长期临床流行病学 艾滋病毒高危吸毒者的治疗结果。这很重要，因为它将指导临床 面对艾滋病毒/艾滋病的持续流行和 药物滥用，包括阿片类药物滥用的流行。许多艾滋病毒感染者的寿命比他们在2000年时更长。 过去，由于高活性抗逆转录病毒疗法的出现和可用性。 我们在20世纪80年代建立了一个独特的吸毒者前瞻性队列， 长期以来，NCI和NIDA建立了无限期持续跟踪的存储库和许可， 对吸毒者的长期研究。这一群体有近11,000名吸毒者，他们在性别、种族、 这些人来自不同的族裔和地域，包括大量艾滋病毒抗体阳性和阴性的人。肝炎 C病毒感染在这些人中非常常见。 我们试图通过两个目标来了解该队列的健康结果。 AIM 1.确定吸毒者中与HIV相关的死亡结局的流行病学特征 在35年的时间里。这将通过将我们的队列与生命统计登记数据相匹配来实现。 AIM 2.为了确定35年期间吸毒者中按癌症部位分列的癌症流行病学， 包括发病率、诊断阶段、治疗方案、死亡率和HIV相关风险。这将是 通过将我们的队列与癌症登记数据相匹配来完成。 我们的项目分析将整合这两种类型的数据，并逐步重复匹配多个 年死亡率数据将使我们能够更准确地对一系列疾病进行生存分析， 结果，特别关注癌症，以确定推定的风险因素。这有可能有助于 确定可减少疾病负担和延长生存期的干预措施。 我们将描述艾滋病毒阳性与艾滋病毒阴性吸毒者相比的疾病结局， 基线人口统计学、行为学和医学因素。我们这群人提供了独特的学习机会， 在几十年的长期时间内， 代表性不足的少数民族。 我们研究的规模以及基线数据的范围和丰富性将使其成为了解 一系列的疾病结果。鉴于生物技术的持续快速发展，未来的研究可能 采用不断发展的生物技术，利用我们的生物标本库来探索特定的疾病结果，我们将 要识别。我们的队列已加入NIDA遗传学联盟。我们将探讨加入其他财团 而这些项目关注的是其他的结果，这些结果可以放大这些财团的力量。